Not Signed In - Lexicon Genetics Files Investigational New Drug Application For LX1031 In Irritable Bowel Syndrome
Wed, 06 Dec 2006 08:00 AM EST
... Lexicon Genetics Incorporated (Nasdaq: LEXG) announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for LX1031, an internally-developed small molecule compound for gastrointestinal disorders such as irritable bowel syndrome. [click link for full article] ...
Related Topics
- Irritable Bowel Syndrome
- Genetics & Genomics
- Genetics
- Irritable Bowel Syndrome in Children
- What I need to know about Irritable Bowel Syndrome
- Irritable Bowel Syndrome Diet
- Irritable Bowel
- Inflammatory Bowel Disease
- Irbesartan
- Marfan Syndrome
- Short Bowel Syndrome
- Chronic Fatigue Syndrome
- Drug Safety
- Prescription Drugs
- Bowel and Intestines
- Genomics & Disease Prevention
- Drug Side Effects
- Syndrome X
- Asperger's Syndrome
- Down Syndrome
email this page
print this page
bookmark this page
feedback on this page
